糖尿病神经病变的全球市场 - 市场规模，占有率，成长分析:障碍，各流通管道，各类药物，产业预测(2022年～2028年)

全球糖尿病神经病变的市场规模在2021年估算为36亿2,638万美金，在预测期间(2023年～2030年)时预计将以6.9％的年复合成长率增长，从2022年的38亿7,660万美元成长到2030年70亿6,725万美元。

本报告提供全球糖尿病神经病变市场相关调查分析，提供市场动态及预测，市场区隔分别分析，企业简介等资讯。

目录

摘要整理

市场概要

亲市场分析

市场概要

市场规模

• 市场动态
• 促进因素
• 机会
• 阻碍因素
• 课题
• SWOT分析

主要的市场洞察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• IP分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 革新矩阵
• 开发中产品分析
• 宏观经济指标

新型冠状病毒的影响

• 简介
• 经济的影响 - Scenario评估
• 市场规模的修正
• 新型冠状病毒对主要市场区隔的影响
• 新型冠状病毒策略:各企业

市场动态及预测

• 市场动态
• 促进因素
• 机会
• 阻碍因素
• 课题
• 法规情形
• SWOT分析
• 波特的五力分析
• 关于未来混乱的特别见解
• 政治影响
• 经济影响
• 社会影响
• 技术性影响
• 环境的影响
• 法律上的影响

全球糖尿病神经病变市场:障碍

• 市场区隔
• 末梢神经病变
• 植物性神经障碍
• 近位神经病变
• 局部神经病变

全球糖尿病神经病变市场:各流通管道

• 市场区隔
• 医院
• 诊疗所
• 零售药局
• 线上药局

市场规模:各地区

• 北美
• 美国
• 加拿大
• 欧洲
• 德国
• 西班牙
• 法国
• 英国
• 其他的欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 韩国
• 其他的亚太地区
• 南美
• 巴西
• 其他的南美
• 中东·非洲
• GCC各国
• 南非
• 其他的中东·非洲

主要企业简介

• 竞争情形
• Johnson & Johnson(美国)
• Boehringer Ingelheim GmbH(德国)
• NeuroMetrix, Inc(美国)
• Eli Lilly and Company(美国)
• GlaxoSmithKline plc(英国)
• Lupin Limited(印度)
• Pfizer Inc(美国)
• Astellas Pharma Inc(日本)
• Glenmark Pharmaceuticals Ltd(印度)
• Arbor Pharmaceuticals, LLC(美国)
• Depomed, Inc(美国)

Global Diabetic Neuropathy Market size was valued at USD 3626.38 million in 2021 and is poised to grow from USD 3876.6 million in 2022 to USD 7067.25 million by 2030, growing at a CAGR of 6.9% in the forecast period (2023-2030).

Diabetic neuropathy is a disorder that affects the nerves and is linked to hyperglycemia. People who have had diabetes for a long time are more prone to have nerve damage throughout their bodies, even when the signs of diabetic neuropathies could not be identified at an early stage. In spite of the fact that diabetic neuropathy cannot be treated, it can be managed or prevented with the aid of a number of therapeutic techniques. Regulating bodies are required to approve more products and therapy techniques that are connected to the condition due to its intricacy. The high prevalence of diabetic neuropathy, which mostly affects diabetic people, will create several expansion opportunities for the companies operating in this industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The Global Diabetic Neuropathy Market segmentation is based on Disorder, Distribution Channel, and Region. Based on disorder the Diabetic Neuropathy Market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Based on distribution channels the Diabetic Neuropathy Market is segmented into hospitals, clinics, retail pharmacies, and online pharmacies. Based on region the global Diabetic Neuropathy market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

An increase in diabetic neuropathy demand due to an increase in diabetes prevalence.

The global demand for diabetic neuropathy will increase more slowly during the projection period due to the increased prevalence of diabetes. Furthermore, it's believed that some of the variables influencing the market's rise include obesity, coronary heart disease, diabetic neuropathy, and other sugar-related problems. Rising urbanisation, which encourages sedentary lifestyles like carbohydrate eating and low physical exercise, also has an impact on the market's expansion.

Expanding R&D efforts by major players to support the diabetic neuropathy market globally.

An rise in the older population and carbohydrate consumption are contributing to an increase in diabetes incidence. As the number of people with diabetes increases worldwide, there is an increasing need for therapies for diabetic neuropathy. The increased government spending to improve health services is also contributing to the market's expansion. Due to the rapid advancement of science and the rising expenditures made by the key industry participants, it is projected that the diabetic neuropathy market would expand in the near future.

Restraint

Expensive prescription drugs and alternative therapies restrain market expansion.

Among the obstacles to market expansion include the rising cost of diabetic neuropathy treatments, the widening selection of complementary therapies, and other factors. The availability of alternative therapies, such as radiotherapy and physical therapy, which are regarded as more comfortable and may offer patients satisfactory clinical outcomes, is one reason restricting the market's development. The strict regulations, product recalls, delays in Food and Drug Administration certifications, and other similar issues may further impede the growth of this industry.

Market Trends

In the upcoming year, high-tech products for better diabetic neuropathy treatment will be produced. Businesses are putting their efforts into developing talc, transdermal patches, and mouthwash, among other things. To address issues with surgical medicines, manufacturers have devised cutting-edge medication delivery technologies, such as syringe-free injection equipment. As a result, NFIT has generated a lot of interest in the disease's therapy, which is aiding the market's growth. Due to the growing need for innovative medication delivery techniques such oral, transdermal, parenteral, and inhalation, the market is growing.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global Global Diabetic Neuropathy Market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
• Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
• (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
• (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
• (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
• (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
• Exhibit: Parent Market Ecosystem Market Analysis
• Exhibit: Market Characteristics of Parent Market
• IP Analysis
• (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
• (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
• (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
• (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
• (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
• (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
• Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
• Exhibit: Data Table on Global Global Diabetic Neuropathy Market size and forecast 2021-2027 ($ million)
• Impact Of COVID On Key Segments
• Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
• COVID Strategies By Company
• Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
• Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
• Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
• Competitive rivalry
• Exhibit: Competitive rivalry Impact of key factors, 2021
• Threat of substitute products
• Exhibit: Threat of Substitute Products Impact of key factors, 2021
• Bargaining power of buyers
• Exhibit: buyers bargaining power Impact of key factors, 2021
• Threat of new entrants
• Exhibit: Threat of new entrants Impact of key factors, 2021
• Bargaining power of suppliers
• Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
• Political Impact
• Economic impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Global Diabetic Neuropathy Market by Disorder
• Market segments
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Data table on Market share 2021-2027 (%)
• Peripheral Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Autonomic Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Proximal Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Focal Neuropathy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Global Global Diabetic Neuropathy Market by Distribution channel
• Market segments
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Data table on Market share 2021-2027 (%)
• Hospitals
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Clinics
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Retail Pharmacy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Online Pharmacy
• Market Estimates & Forecast, 2020-2027
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

• Chart on Market share by geography 2021-2027 (%)
• Data Table on Market share by geography 2021-2027(%)
• North America
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• USA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Canada
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Europe
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• Germany
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Spain
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• France
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• UK
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of Europe
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Asia Pacific
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• China
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• India
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Japan
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• South Korea
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of Asia Pacific
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Latin America
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• Brazil
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of South America
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Middle East & Africa (MEA)
• Chart on Market share by country 2021-2027 (%)
• Data Table on Market share by country 2021-2027(%)
• GCC Countries
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• South Africa
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)
• Rest of MEA
• Exhibit: Chart on Market share 2021-2027 (%)
• Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
• Total number of companies covered
• Exhibit: companies covered in the report, 2021
• Top companies market positioning
• Exhibit: company positioning matrix, 2021
• Top companies market Share
• Exhibit: Pie chart analysis on company market share, 2021(%)
• Johnson & Johnson (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Boehringer Ingelheim GmbH (Germany)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• NeuroMetrix, Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Eli Lilly and Company (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• GlaxoSmithKline plc (UK)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Lupin Limited (India)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Pfizer Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Astellas Pharma Inc (Japan)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Glenmark Pharmaceuticals Ltd (India)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Arbor Pharmaceuticals, LLC (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments
• Depomed, Inc (US)
• Exhibit Company Overview
• Exhibit Business Segment Overview
• Exhibit Financial Updates
• Exhibit Key Developments